- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (66)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (26)
- Bladder Cancer (68)
- Brain Metastases (28)
- Brain Tumor (230)
- Breast Cancer (718)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (154)
- Colon Cancer (164)
- Colorectal Cancer (112)
- Endocrine Tumor (4)
- Esophageal Cancer (42)
- Eye Cancer (36)
- Fallopian Tube Cancer (6)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (8)
- Kidney Cancer (126)
- Leukemia (344)
- Liver Cancer (50)
- Lung Cancer (288)
- Lymphoma (284)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (98)
- Myelodysplastic Syndrome (60)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (100)
- Ovarian Cancer (170)
- Pancreatic Cancer (164)
- Parathyroid Disease (2)
- Penile Cancer (14)
- Pituitary Tumor (6)
- Prostate Cancer (144)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (236)
- Skin Cancer (296)
- Skull Base Tumors (56)
- Spinal Tumor (12)
- Stomach Cancer (60)
- Testicular Cancer (28)
- Throat Cancer (90)
- Thymoma (6)
- Thyroid Cancer (96)
- Tonsil Cancer (30)
- Uterine Cancer (78)
- Vaginal Cancer (14)
- Vulvar Cancer (18)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (10)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (630)
- Complementary Integrative Medicine (24)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (230)
- Epigenetics (6)
- Fertility (62)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (124)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (118)
- Molecular Diagnostics (8)
- Pain Management (62)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (906)
- Research (394)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (606)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (402)
- Survivorship (322)
- Symptoms (184)
- Treatment (1776)
Help from a new drug: Treating my breast cancer recurrence
3 minute read | Published June 17, 2013
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on June 17, 2013
Even though I knew the odds were against me, I didn't want to face my reality. I have too much I want to do before I die.
But wishing wouldn't my change reality: My estrogen positive (ER+) breast cancer had returned.
My breast cancer treatment
My personal war against stage 3 breast cancer began on May 10, 2005.
Since then, I've endured eight rounds of chemotherapy (lost my hair), a mastectomy, 25 radiation treatments, staph infection, wound VAC for 30 days, a frozen shoulder, a year of physical therapy and reconstructive surgery, with seven surgeries total.
So it was game on for my breast cancer -- war two -- when my oncologist called me on June 29, 2012, to say there were metastatic breast cancer tumors in my lungs and bones. My stage was elevated to 4.
I quickly started on Faslodex®, a drug used to treat hormone receptor-positive breast cancer. Unfortunately, my cancer kept growing, so it was time for plan B. My oncologist Ricardo Alvarez, M.D., suggested everolimus (Afinitor) with tamoxifen.
Afinitor is a new FDA-approved drug that's also used to treat hormone receptor-positive breast cancer. It's used in patients like me who've already received other treatments that didn't work well.
I've also been on Xgeva® since my recurrence. It requires a shot every month.
Good news, thanks to Afinitor
I was at MD Anderson in May 2013 when Dr. Alvarez told me the news.
There I was, walking out of MD Anderson, trying to avoid the people, cars and shuttles. It was 5:00 pm, and I remember stopping in my tracks when he called.
I just stood there trying to be normal, but I wanted to shout for joy and drop to my knees. Dr. Alavarez had received a few of the reports from the scans I'd just finished. It was good news -- very good news.
Several of the tumors were completely gone, and the remaining ones had shrunk. It was a miracle.
Dr. Alvarez told me I had reason to celebrate. I was happy in a numb sort of way.
Killing my cancer
All I really wanted to do was order room service and watch a movie at my hotel. It's been a long 11 months filled with so many emotions, acres of drugs and tests, lots of time devoted to my health care and an every-day-every-moment determination to focus my faith.
I saw the scans the next afternoon. It was only when I saw proof that I really understood what Afintor had done. It was killing my cancer.
I started shaking.
Thanks to the FDA's approval, doctors have just begun using this drug to treat advanced breast cancer. Good timing for me.
The battle continues
But the battle continues. Thankfully, Afinitor is working. I will continue to take it and hopefully the side effects will diminish. Currently, I deal with the common ones such as mouth sores, nausea and fatigue.
Often, I'm told how good I look. If you've been one of the kind people delivering a compliment, thank you.
I suspect people think I should look like a stereotypical cancer patient -- thin, bald, sick. What people can't see is my doctoring routine morning and night. I use more lotions, creams, rinses and ointments than can fit on my bathroom countertop.
The most important part of my routine is wrapping the miracle Afinitor pill inside a marshmallow.
I swallow it and, with each dose, I pray, "Please kill all the cancer and spare my life."

I swallow (Afinitor pill) and, with each dose, I pray, 'Please kill all the cancer and spare my life.'
Donna Patricia Brown
Survivor